Likewise, Fasn and Srebf1 mRNA levels in the liver were reduced by the presence of GCGRant (Fig
In the United States, the Food and Drug Administration (FDA) has a program called MedWatch where you can report any adverse effects
What stood out is that the conversation seems to be shifting from asking, "How much weight can we achieve?" to "For which patient do the overall benefits truly outweigh the long-term trade-offs?" I'm curious: when efficacy, adverse effects, lean-mass loss, and durability point in different directions, what most often helps you recognize that one path has become the right one for an individual patient
Maybe to start, on this segment of the show we talk about for a given company, how much value do they create in the world versus how much they capture
All use must comply with institutional and regulatory requirements
Peptides potentially accelerating fusion and reducing non-union risk